Research paperDuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing
Under a Creative Commons license
open access
Keywords
Bispecific antibody
CD3
CD20
T cell redirection
B cell malignancy
Subcutaneous administration
Cited by (0)
- 1
Current affiliations: Dept of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands and Lava Therapeutics, Utrecht, The Netherlands.
- 2
These authors contributed equally to this work.
© 2020 The Authors. Published by Elsevier B.V.